ENXTPA:SANPharmaceuticals
Sanofi (ENXTPA:SAN) Valuation Check After Dupixent Secures Japanese Approval In Rare Skin Disease
Sanofi (ENXTPA:SAN) is back in focus after Japan approved Dupixent for adults with moderate to severe bullous pemphigoid, a rare skin disease. This adds another immunology indication to its portfolio.
See our latest analysis for Sanofi.
News around Dupixent and other rare disease programs has coincided with a short-term lift, with a 1-day share price return of 1.36% and 7-day share price return of 3.84%, although the 1-year total shareholder return of 16.82% and 3-year total shareholder...